Alnylam Pharmaceuticals, Inc. ALNY
$228.65
+0.67%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 10-Q | 10-Q | 2026-07-30 | View → |
| 8-K | 8-K | 2026-07-30 | View → |
| 4 | PRIMARY DOCUMENT | 2026-06-03 | View → |
| 4 | PRIMARY DOCUMENT | 2026-06-03 | View → |
| 8-K | 8-K | 2026-05-27 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-22 | View → |
| 4 | PRIMARY DOCUMENT | 2026-05-14 | View → |
| 10-Q | 10-Q | 2026-04-30 | View → |
| 8-K | 8-K | 2026-04-30 | View → |
| 4 | PRIMARY DOCUMENT | 2026-04-07 | View → |
| DEF 14A | DEF 14A | 2026-04-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-06 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-04 | View → |
| 8-K | 8-K | 2026-03-04 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-02 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-02 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-02 | View → |
| 4 | PRIMARY DOCUMENT | 2026-03-02 | View → |
| 4 | PRIMARY DOCUMENT | 2026-02-25 | View → |
| 4 | PRIMARY DOCUMENT | 2026-02-17 | View → |
| 4 | PRIMARY DOCUMENT | 2026-02-17 | View → |
| 4 | PRIMARY DOCUMENT | 2026-02-17 | View → |
| 4 | PRIMARY DOCUMENT | 2026-02-17 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $228.65
- Market Cap
- $29.97 billion
- 52-Week Range
- $197.81 – $495.55
- Average Volume
- 2.13 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.